iCo Therapeutics Recruits Leading Ophthalmologist to Strategic Advisory Board

    VANCOUVER, June 14 /PRNewswire/ - iCo Therapeutics Inc. announced today
 that Dr. Philip Rosenfeld has joined iCo's strategic advisory team. Dr.
 Rosenfeld is Professor of Ophthalmology at the world-renowned Bascom Palmer
 Eye Institute at the University of Miami, Miller School of Medicine.
     "Dr. Rosenfeld has been involved in the clinical testing of virtually
 every medical treatment for age-related macular degeneration (AMD) and was
 the first to demonstrate the usefulness of Avastin in treating the
 disease," said Andrew Rae, iCo President and CEO. "Dr. Rosenfeld's vision
 and pioneering efforts with Avastin have led to a paradigm shift in the way
 AMD is treated today. We are extremely pleased to have him join our
 strategic advisory board and help guide the acquisition and clinical
 development of our products."
     Dr. Rosenfeld's chief research interests are in the diagnosis,
 treatment and genetics of macular diseases. He is at the forefront of
 medical testing having spent the past decade seeking effective therapies
 for AMD. He is currently Principal Investigator of nine clinical trials for
 AMD. In May 2005, Dr. Rosenfeld was the first to perform an intravitreal
 injection of Avastin - a drug approved to treat colon cancer - for the
 treatment of wet AMD. By injecting a small amount of the drug into the eyes
 of patients with wet AMD, Dr. Rosenfeld showed that Avastin not only halted
 the progression of neovascularization in these patients, but also resulted
 in an improvement in vision in many of the patients. These findings have
 since been put into practice by physicians around the world.
     Dr. Rosenfeld received a Medical Degree and PhD from the Johns Hopkins
 University School of Medicine in Baltimore. He completed a residency at
 Harvard's Massachusetts Eye and Ear Infirmary and fellowships at both the
 Department of Ophthalmology at Harvard University and the Bascom Palmer Eye
 Institute at the University of Miami, Miller School of Medicine.
     iCo Therapeutics Inc. is an emerging, Vancouver-based biotechnology
 company focused on developing pre-existing drugs for a range of new
 conditions affecting isolated biological environments-areas such as the
 eye, spinal cord, or joints-where locally-administered application of these
 therapies would have minimal systemic distribution and fewer safety issues.
     For more information, visit the company website at:
 www.icotherapeutics.com
     Business Development Contact:              Finance/Investor Contact:
     Dr. John Clement, CT&DO                    Mr. John Meekison, CFO
     778.688.0644                               604.602.9414
 
     Media Contact:
     Amanda Smith, Principal, Smith Biotech
     604.626.6264
 
 

SOURCE iCo Therapeutics Inc.

More by this Source


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.